![1]()
News
Empagliflozin cut PA pressures in heart failure patients
October 12, 2020
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
October 6, 2020
Empagliflozin treatment of HFrEF was equally beneficial regardless of whether patients also received sacubitril/valsartan.
![1]()
News
Dapagliflozin’s CKD performance sends heart failure messages
October 5, 2020
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians.
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
October 1, 2020
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression.
![1]()
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
September 25, 2020
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25.
![1]()
News
Obesity boosts risks in COVID-19 from diagnosis to death
September 1, 2020
Excess pounds are linked to excess infection, hospitalization, ICU admission, and mortality.
![1]()
News
Gut bacteria linked to cardiovascular, other health conditions
August 31, 2020
“Microbiota and their metabolites ... could serve as potential therapeutic targets for the maintenance of health and prevention and treatment of cardiovascular diseases.”
![1]()
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
August 31, 2020
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
August 30, 2020
The 25% cut in primary endpoints among HFrEF patients on empagliflozin matched the benefit seen before from dapagliflozin in DAPA-HF.
News
Batten down the hatches for thyroid storm
August 28, 2020
“The big thing is to look for and treat the underlying precipitating event.”
